Domestic market will soon be listed in the United States, the United States and the withdrawal of th 特命战队go busters

The upcoming vaccine has been in the United States delisting experts: not the effect is not good stock market center: exclusive national industry sector stocks, premarket after hours, ETF, real-time quotes of the Beijing News (reporter Dai Xuan) GlaxoSmithKline (GSK) suitable for production of "" Siri (human papilloma virus vaccine) in July this year to obtain licensed Chinese food and drug administration, became the first approved for the prevention of cervical cancer vaccine HPV. However, after 3 months, there is news that the upcoming listing of Sri China fitness has been in the United States to withdraw from the market, caused a lot of attention. Yesterday, GlaxoSmithKline confirmed to the Beijing News reporter, said SRI and listed in the United States. The license is still valid. In July this year, the State Food and Drug Administration announcement, 12 month approved GlaxoSmithKline (GSK), preventive biological products — the human papilloma virus vaccine adsorbed import registration. This means that the first vaccine to be able to prevent cancer – cervical cancer vaccine (also known as HPV vaccine) in the international market for 10 years, and finally got the identity of the Chinese listed on the license. However, recently there is news that the upcoming listing of Sri China fitness is currently in the United States delisting. Many netizens questioned just in China approved near SRI is "out of stock". Yesterday, GlaxoSmithKline confirmed "in the United States withdraw Siri" message to the Beijing News reporter, but said, but suitable listed in the United States license is still valid. In addition, GSK also said, according to the U.S. Centers for Disease Control and Prevention (CDC) of the Advisory Committee on Immunization Practices (ACIP) recently released information, the U.S. market is currently only use HPV9 HPV4 vaccine and bivalent vaccine, 2 valent vaccine have stopped supply. Listed on the China approved Siri is HPV2 vaccine (suitable price can be 16 and 18 of two immune virus subtype), the suitable inoculation population was 9 to 25 years old women, the 3 immunization vaccination program, is expected to be officially listed at the beginning of next year. It is understood that cervical cancer is China women aged 15 to 44 years old in the second high incidence of cancer, about 13 million new cases every year, every year Chinese cervical cancer cases accounted for more than 28% of the world. Human papillomavirus (HPV) infection is the main cause of cervical cancer. Question 1 delisting will affect the listing in China? But in China does not affect the listing plan; the initial price is not too expensive in 2009, but it is understood that the appropriate approved by the US FDA, for the prevention of cancer type HPV16 and type 18 causes including cervical cancer disease. The stop supply in the United States, will affect the upcoming listing of Sri China suitable? GlaxoSmithKline said that the market for the United States decided not to influence other market supply, no influence in Sri Chinese listing plan, will be listed. GSK also said that in addition to other suitable tome market outside the US are still in use, has been listed in the global 136 countries and regions currently approved, with more than 61 million agents and Cong to the global market相关的主题文章: